Galera intends to leverage NCI grants, academic partnerships and the I-SPY 2 network for efficient and cost-effective ...

MALVERN, PA — Galera Therapeutics, Inc. (OTC: GRTX) has announced its acquisition of Nova Pharmaceuticals, Inc., a ...

Lead program is Phase 1/2 trial of Nova Pharmaceutical’s Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer.

We have found that treatment of sea urchin embryos with chlorate, a competitive inhibitor of sulfation of proteoglycans via PAPS synthase ... We are investigating the development of the larval nervous ...